Loading...
Market
FDA New Mifepristone Regulations by End of 2024?
5
Resolution / Starting Odds
Yes • 50%
No • 50%
FDA announcements, official press releases
Story
Supreme Court Preserves Access to Mifepristone in Unanimous 9-0 Decision
Jun 15, 2024, 10:22 PM
The U.S. Supreme Court has unanimously ruled in a 9-0 decision that anti-abortion groups lack the standing to challenge the FDA's approval of mifepristone, a drug commonly used in medication abortions. This decision preserves access to the abortion pill, which can be mailed to patients without in-person visits. The ruling is seen as a significant victory for abortion rights advocates, but both sides acknowledge that the legal battles over mifepristone and other reproductive rights are far from over. The case marks the first major abortion-related decision by the Supreme Court since the overturning of Roe v. Wade in 2022. The ruling also addressed the FDA's 2016 and 2021 rule changes on mifepristone.
View original story
Similar markets
Yes • 50%
No • 50%
Yes • 50%
No • 50%
California • 25%
Texas • 25%
Florida • 25%
New York • 25%
Increase production • 33%
Maintain current levels • 33%
Decrease production • 33%
Increase in support • 33%
Decrease in support • 33%
No significant change • 34%
